Cardinal Health earnings ahead: Can profit growth continue?

Cardinal Health is set to report fiscal Q4 results with analysts expecting EPS of $2.42 on revenue of $65.03B, including +6.8% sequential revenue growth but -23.6% YoY EPS decline vs $3.17 in Q3. Street sentiment is constructive ahead of the print, with 17 “Strong Buy” ratings and a mean $252.40 price target (~+6.8% vs $236.40), alongside recent estimate upticks (+0.41% EPS over 60 days). The key watch items are the durability of margin expansion (EBITDA +26% and operating income +27.8%) amid razor-thin gross margins (3.76%) and potential cost/regulatory overhang from recent levothyroxine recall activity.

Analysis

CAH is trading like a quality compounder rather than a low-margin distributor, which makes the setup more about expectations than fundamentals. The near-term risk is not the print itself but whether management can keep converting incremental revenue into margin at the same pace; if operating leverage normalizes, the current multiple leaves less room for a “good but not great” quarter. In other words, the stock likely needs a clean guide-up to justify staying near highs; a simple beat with flat forward commentary is more likely to trigger multiple compression than another leg higher.

The second-order issue is competitive, not accounting: if direct-to-patient channels keep expanding, the weakest link is likely smaller wholesalers and pharmacy-adjacent intermediaries that rely on scale but lack specialty mix. CAH’s scale should still protect share, but the market is paying for resilience, so any incremental quality-control or compliance costs will be punished disproportionately because they hit a business with very low gross margins and high fixed-cost sensitivity. Over the next 1-3 months, analyst revisions will matter more than the print; over 6-18 months, the key question is whether specialty/pharma mix can offset channel disintermediation.

Contrarian view: consensus may be overconfident that recent margin expansion is structural. The better risk/reward is that CAH can keep compounding, but the upside from here is probably smaller than headline growth suggests because the market is already discounting execution perfection. The thesis is falsified if management raises FY guidance again and quantifies margin gains as repeatable rather than one-off; otherwise, a small miss on revenue or a cautious tone on quality/regulatory costs could reset the multiple quickly.

Key Decisions for Investors

• Do not initiate fresh long CAH into the print; wait for management guidance and only add on a post-earnings break above the recent high with raised full-year EPS outlook.
• Relative-value trade: short CAH / long MCK for the next 1-3 months, betting that CAH’s premium multiple is more vulnerable if margin expansion decelerates while MCK’s scale and mix support a steadier re-rate.
• If already long CAH, hedge into earnings with short-dated puts or a put spread targeting a 5-8% drawdown; thesis breaks if guidance is raised materially and revenue/EBITDA are both above consensus.
• Watch for any explicit increase in compliance/recall costs or commentary on channel disruption; if those items are quantified as immaterial, cover hedges on the first post-print pullback.
• Set an alert on CAH’s forward P/E versus historical range: if the stock holds near highs but the multiple expands further without a second guidance raise, fade strength rather than add.